Product Research Guide
Retatrutide and GLP-3R Research: Understanding Triple-Receptor Agonism
Retatrutide, cataloged by Alquimia as GLP-3R, is an investigational peptide agonist studied across three metabolic receptor systems: GLP-1, GIP, and glucagon.
Reviewed · August 18, 2026
Why It Is Called a Triple Agonist
The published phase 2 literature describes retatrutide as a single molecule designed to activate GLP-1, GIP, and glucagon receptors. Researchers evaluate how combined receptor activity affects metabolic signaling rather than treating the three pathways as isolated systems.
Common Research Endpoints
Published studies have measured body weight, waist circumference, glucose-related variables, lipids, appetite-related outcomes, adverse events, and heart rate. Each result depends on the tested dose, study population, duration, and protocol.
- GLP-1 receptor signaling
- GIP receptor signaling
- Glucagon receptor signaling
- Body-weight and body-composition endpoints
- Glucose and lipid variables
Investigational Status Matters
Retatrutide remains an investigational compound. Alquimia supplies GLP-3R only as a laboratory research material; the published clinical literature should be read as scientific evidence, not as a dosing or treatment guide.